Wave Life Sciences Ltd. (NASDAQ:WVE) Expected to Post FY2025 Earnings of ($1.29) Per Share

Wave Life Sciences Ltd. (NASDAQ:WVE) – Leerink Partnrs dropped their FY2025 earnings estimates for shares of Wave Life Sciences in a report released on Tuesday, June 25th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($1.29) per share for the year, down from their previous estimate of ($1.25). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($0.85) per share.

A number of other analysts also recently issued reports on the stock. Mizuho reissued an “outperform” rating and set a $19.00 target price on shares of Wave Life Sciences in a research report on Tuesday, June 25th. Royal Bank of Canada restated a “sector perform” rating and set a $5.00 price objective on shares of Wave Life Sciences in a research note on Thursday, March 7th. Truist Financial reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Wave Life Sciences in a research report on Monday, April 1st. Wells Fargo & Company began coverage on shares of Wave Life Sciences in a research report on Wednesday, May 15th. They set an “overweight” rating and a $11.00 target price on the stock. Finally, StockNews.com lowered shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.29.

Wave Life Sciences Price Performance

NASDAQ:WVE opened at $4.99 on Friday. The company has a market cap of $611.13 million, a P/E ratio of -9.60 and a beta of -1.03. The firm’s 50 day moving average is $5.72 and its two-hundred day moving average is $5.31. Wave Life Sciences has a fifty-two week low of $3.50 and a fifty-two week high of $7.67.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $12.54 million for the quarter, compared to analyst estimates of $25.67 million. During the same quarter in the prior year, the firm posted ($0.27) EPS.

Insider Buying and Selling at Wave Life Sciences

In other news, CFO Kyle Moran sold 15,630 shares of Wave Life Sciences stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $6.17, for a total value of $96,437.10. Following the completion of the transaction, the chief financial officer now owns 33,921 shares in the company, valued at approximately $209,292.57. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 31.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of WVE. Ameritas Investment Partners Inc. lifted its stake in Wave Life Sciences by 50.2% in the first quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock valued at $45,000 after buying an additional 2,451 shares during the last quarter. Swiss National Bank boosted its position in shares of Wave Life Sciences by 2.7% during the first quarter. Swiss National Bank now owns 156,500 shares of the company’s stock worth $966,000 after buying an additional 4,100 shares during the period. Capstone Investment Advisors LLC grew its holdings in Wave Life Sciences by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 54,500 shares of the company’s stock worth $336,000 after buying an additional 4,500 shares in the last quarter. ProShare Advisors LLC increased its position in Wave Life Sciences by 35.0% in the 1st quarter. ProShare Advisors LLC now owns 21,764 shares of the company’s stock valued at $134,000 after acquiring an additional 5,648 shares during the period. Finally, American International Group Inc. raised its stake in Wave Life Sciences by 23.3% during the 1st quarter. American International Group Inc. now owns 36,241 shares of the company’s stock valued at $224,000 after acquiring an additional 6,851 shares in the last quarter. 89.73% of the stock is owned by institutional investors and hedge funds.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.